Shares of Insmed (NASDAQ: INSM) plummeted 5.07% in Thursday's trading session following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical company, known for its inhaled antibiotic ARIKAYCE, reported a wider-than-expected loss and maintained a conservative revenue outlook, sparking concerns among investors.
Insmed reported a Q1 net loss of $1.42 per diluted share, significantly worse than the $1.06 loss per share in the same quarter last year and missing the FactSet analyst consensus estimate of $1.34 per share. The company's net loss for the quarter reached $256.6 million, also surpassing the expected loss of $240.4 million. Despite the challenges on the bottom line, Insmed's Q1 revenue showed some positive momentum, coming in at $92.8 million, slightly above the analyst estimate of $92.1 million and representing a 22.94% increase from the previous year.
Adding to investor concerns, Insmed maintained its full-year 2025 global ARIKAYCE product revenue guidance at $405 million to $425 million. This outlook falls short of the $468.4 million expected by analysts polled by FactSet, suggesting potential headwinds in the company's growth trajectory. The combination of wider losses, missed earnings estimates, and a conservative revenue forecast appears to have dampened investor enthusiasm, leading to the significant stock decline during Thursday's trading session.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。